The invention relates to UBE3A protein targets and their usage as target engagement biomarkers for compounds that modulate ube3a expression.

The present invention relates to peptides and peptidomimetics as well as their medical use in the treatment of hyperproliferative diseases and inflammatory diseases.

Bacterial systems for analyzing ubiquitination of proteins is disclosed herein. Kits for analyzing the ubiquitination and methods for carrying out the analysis are also disclosed.

Disclosed are methods for identifying an agent of interest that alters binding or activity of a client protein to a chaperone and kits thereof.

Disclosed are a biomarker, method and assay kit for identifying and screening for urothelial carcinoma (UC) in a subject in need.

Isolated histidyl-tRNA synthetase splice variant polynucleotides and polypeptides having non-canonical biological activities are provided, as well as compositions and methods related thereto.

Provided is use of E3 ubiquitin ligase Nedd4-1 in preparation of a drug for inhibiting the Ras protein level. Also provided is use in preparation of a drug for preventing and/or treating tumors or a drug for prolonging the life span of organisms.

The present invention relates to a method for diagnosing pancreatic cancer using methionyl-tRNA synthetase (MRS). When used as a pancreatic cancer marker, MRS has a significantly higher level of diagnostic accuracy than conventional pancreatic cancer markers such as CEA; thus, analyzing the expression status of methionyl-tRNA synthetase (MRS) in pancreatic cells has the effect of clearly determining the presence or absence of pancreatic cancer, and said effect is likewise exhibited even in the cells that have been determined to be atypical cells by a general staining technique, and thus can be very useful in the diagnosis of pancreatic cancer.

The present disclosure relates to the use of genes whose expression or protein changes specifically to hepatocellular carcinoma as biomarkers for the detection and diagnosis of hepatocellular carcinoma, in which the biomarkers of the present disclosure, HMMR, NXPH4, PITX1, THBS4, and UBE2T, since they change their expression specifically to hepatocellular carcinoma, may be used as hepatocellular carcinoma-specific markers, and furthermore, these biomarkers may be used independently or in combination with AFP, or may be independently combined to make a more specific and accurate diagnosis of hepatocellular carcinoma.

The present disclosure relates to an antibody binding specifically to tryptophanyl-tRNA synthetase (WARS) or a fragment thereof. The antibody or the fragment thereof of the present disclosure has an excellent ability to bind specifically to WARS with no cross-reactivity with other ARSs and has an excellent ability to detect WARS and inhibit the activity thereof. Therefore, it can be effectively used for diagnosing and/or treating an infectious disease.